@article{094246457de74cdd96868476796a9c9a,
title = "Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years",
abstract = "To assess long-term drug survival and effectiveness in biological drug-na{\"i}ve patients with rheumatoid arthritis (RA), starting infliximab as first treatment, in the period 2000-2009, comparing different calendar years.",
keywords = "Adult, Aged, Antibodies, Monoclonal, Antirheumatic Agents, Arthralgia, Arthritis, Rheumatoid, C-Reactive Protein, Demography, Disability Evaluation, Female, Humans, Infliximab, Italy, Kaplan-Meier Estimate, Male, Middle Aged, Pain Measurement, Patient Acuity, Patient Outcome Assessment, Registries, Remission Induction, Rheumatoid Factor, Time-to-Treatment, Adult, Aged, Antibodies, Monoclonal, Antirheumatic Agents, Arthralgia, Arthritis, Rheumatoid, C-Reactive Protein, Demography, Disability Evaluation, Female, Humans, Infliximab, Italy, Kaplan-Meier Estimate, Male, Middle Aged, Pain Measurement, Patient Acuity, Patient Outcome Assessment, Registries, Remission Induction, Rheumatoid Factor, Time-to-Treatment",
author = "Elisa Gremese and Florenzo Iannone and Fausto Salaffi and Antonio Marchesoni and Roberto Gorla and Fabiola Atzeni and Marcello Govoni and Giovanni Lapadula and Favalli, {E. G.} and C. Bazzani and P. Sarzi-Puttini and S. Lopriore and C. Caimmi",
year = "2015",
language = "English",
volume = "33",
pages = "524--530",
journal = "CLINICAL AND EXPERIMENTAL RHEUMATOLOGY",
issn = "1593-098X",
publisher = "Pisa: Clinical and Experimental Rheumatology.",
}